Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Dec;89(12):1318–1325. doi: 10.1111/j.1349-7006.1998.tb00529.x

Anti‐cachectic Effect of FK317, a Novel Anti‐cancer Agent, in Colon26 and LX‐1 Models in Mice

Yoshinori Naoe 1,✉, Ikuo Kawamura 1, Masamichi Inami 1, Sanae Matsumoto 1, Fusako Nishigaki 1, Susumu Tsujimoto 1, Toshitaka Manda 1, Kyoichi Shimomura 1
PMCID: PMC5921729  PMID: 10081493

Abstract

The effects of FK317 (11‐acetyl‐8‐carbamoyloxymethyl‐4‐formyl‐6‐methoxy‐14‐oxa‐1,11‐diazatetra‐cyclo[7.4.1.02,7.010,2]tetradeca‐2,4,6‐trien‐9‐yl acetate), a novel anti‐cancer agent, on murine adenocarcinoma colon26‐ and human lung carcinoma LX‐1‐induced cachexia were investigated in mice. Mice bearing colon26 or LX‐1 s.c. lost weight and became cachectic, associated with tumor growth. FK317 and mitomycin C (MMC) inhibited the growth of both tumors. FK317 ameliorated the weight loss induced by the presence of colon26 or LX‐1, while MMC enhanced it. An attenuation of the reduction in the weights of epididymal fat, gastrocnemius muscle and carcass was observed in FK317‐treated tumor‐bearing mice in both cachexia models, but not in MMC‐treated mice. The decreases in the circulating levels of triglyceride, glucose and non‐esterified fatty acid, which were induced by the presence of colon26, was partially inhibited by treatment with FK317. Overall, this study revealed that FK317 is a potent anti‐cancer drug with anti‐cachectic activity, suggesting that FK317 has potential utility for the treatment of cancer.

Keywords: FK317, LX‐1, Colon26, Cachexia, Weight loss

Full Text

The Full Text of this article is available as a PDF (134.0 KB).

REFERENCES

  • 1. ) Shimomura , K. , Manda , T. , Mukumoto , S. , Masuda , K. , Nakamura , T. , Mizota , T. , Matsumoto , S. , Nishigaki , F. , Oku , T. , Mori , J. and Shibayama , F.Antitumor activity and hematotoxicity of a new, substituted dihydrobenzox‐azine, FK973, in mice . Cancer Res. , 48 , 1166 – 1172 ( 1988. ). [PubMed] [Google Scholar]
  • 2. ) Iwami , M. , Kiyoto , S. , Terano , H. , Kohsaka , M. , Aoki , H. and Imanaka , H.A new antitumor antibiotic, FR‐900482 (I). Taxonomic studies on the producing strain: a new species of genus Streptomyces . J. Antibiot. (Tokyo) , 40 , 589 – 593 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Kiyoto , S. , Shibata , T. , Yamashita , M. , Komori , T. , Okuhara , M. , Terano , H. , Kohsaka , M. and Aoki , H.A new antitumor antibiotic, FR‐900482 (II). Production, isolation, characterization and biological activity . J. Antibiot. (Tokyo) , 40 , 594 – 599 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Shimomura , K. , Hirai , O. , Mizota , T. , Matsumoto , S. , Mori , J. , Shibayama , F. and Kikuchi , H.A new antitumor antibiotic, FR‐900482 (III). Antitumor activity in transplantable experimental tumors . J. Antibiot. (Tokyo) , 40 , 600 – 606 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Majima , H. , Hasegawa , K. , Fukuoka , M. , Furuse , K. , Wakui , A. , Furue , H. , Masaoka , T. , Hattori , T. , Taguchi , T. , Ogura , T. and Niitani , H.Phase I clinical and pharmacokinetic study of FK973 . Proc. Am. Soc. Clin. Oncol. , 9 , 78 ( 1990. ). [Google Scholar]
  • 6. ) Pazdur , R. , Ho , D. H. , Daugherty , K. , Bradner , W. T. , Krakoff , I. H. and Raber , M. N.Phase I trial of FK973: description of a delayed vascular leak syndrome . Invest. New Drugs , 9 , 377 – 382 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Naoe , Y. , Inami , M. , Matsumoto , S. , Nishigaki , F. , Tsujimoto , S. , Kawamura , I. , Miyayasu , K. , Manda , T. and Shimomura , K.FK317; a novel substituted dihydrobenzoxazine with potent antitumor activity and without inducing vascular leak syndrome . Cancer Chemother. Pharmacol. , 42 , 31 – 36 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) DeWys , W. D. , Begg , C. , Lavin , P. T. , Band , P. R. , Bennett , J. M. , Bertino , J. R. , Cohen , M. H. , Douglass , H. O. , Engstrom , P. F. , Ezdinli , E. Z. , Horton , J. , Johnson , G. J. , Moertel , C. G. , Oken , M. M. , Perlia , C. , Rosenbaum , C. , Silverstein , M. N. , Skeel , R. T. , Sponzo , R. W. and Tormey , D. C.Prognostic effect of weight loss prior to chemotherapy in cancer patients . Am. J. Med. , 69 , 491 – 497 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Lazo , P. A.Tumor‐host metabolic interaction and cachexia . FEBS Lett. , 187 , 189 – 192 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Curtis , E. B. , Krech , R. and Walsh , T. D.Common symptoms in patients with advanced cancer . J. Palliat. Care , 7 , 25 – 29 ( 1991. ). [PubMed] [Google Scholar]
  • 11. ) Kern , K. A. and Norton , J. A.Cancer cachexia . J. Parenter. Enteral Nutr. , 12 , 286 – 298 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Corbett , T. H. , Griswold , D. P. , Jr. , Robert , B. J. , Peckham , J. C. and Schabel , F. M. , Jr.Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure . Cancer Res. , 35 , 2434 – 2439 ( 1975. ). [PubMed] [Google Scholar]
  • 13. ) Tanaka , Y. , Eda , H. , Tanaka , T. , Udagawa , T. , Ishikawa , T. , Horii , I. , Ishitsuka , H. , Kataoka , T. and Taguchi , T.Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice . Cancer Res. , 50 , 2290 – 2295 ( 1990. ). [PubMed] [Google Scholar]
  • 14. ) Goldin , A. , Venditti , J. M. , Macdonald , J. S. , Muggia , F. M. , Henney , J. E. and Devita , V. T. , Jr.Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute . Eur. J. Cancer , 17 , 129 – 142 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Tashiro , T. , Inaba , M. , Kobayashi , T. , Sakurai , Y. , Maruo , K. , Ohnishi , Y. , Ueyama , Y. and Nomura , T.Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses . Cancer Chemother. Pharmacol. , 24 , 187 – 192 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Strassmann , G. , Fong , M. , Kenney , J. S. and Jacob , C. O.Evidence for the involvement of interleukin 6 in experimental cancer cachexia . J. Clin. Invest. , 89 , 1681 – 1684 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Strassmann , G. , Jacob , C. O. , Evans , R. , Beall , D. and Fong , M.Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon‐26 carcinoma and its relevance to IL‐6‐mediated cancer cachexia . J. Immunol. , 148 , 3674 – 3678 ( 1992. ). [PubMed] [Google Scholar]
  • 18. ) Strassmann , G. , Masui , Y. , Chizzonite , R. and Fong , M.Mechanisms of experimental cancer cachexia: local involvement of IL‐1 in colon‐26 tumor . J. Immunol. , 150 , 2341 – 2345 ( 1993. ). [PubMed] [Google Scholar]
  • 19. ) Yamamoto , N. , Kawamura , I. , Nishigaki , F. , Tsujimoto , S. , Naoe , Y. , Inami , M. , Lacey , E. , Manda , T. and Shimomura , K.Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon26‐induced cachexia in mice . Anticancer Res. , 18 , 139 – 144 ( 1998. ). [PubMed] [Google Scholar]
  • 20. ) Kawamura , I. , Morishita , R. , Tomita , N. , Lacey , E. , Aketa , M. , Tsujimoto , S. , Manda , T. , Tomoi , M. , Kida , I. , Higaki , J. , Kaneda , Y. , Shimomura , K. and Ogihara , T.Injection of oligonucleotides to NF′B binding site specifically inhibited cachexia in a mouse tumor model . Gene Ther. , 5 ( 1998. ), in press . [DOI] [PubMed] [Google Scholar]
  • 21. ) Naoe , Y. , Inami , M. , Matsumoto , S. , Takagaki , S. , Fujiwara , T. , Yamazaki , S. , Kawamura , I. , Nishigaki , F. , Tsujimoto , S. , Manda T. and Shimomura , K.FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice . Jpn. J. Cancer Res. , 89 , 1306 – 1317 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES